Ceribell Receives FDA Breakthrough Designation for LVO Stroke Detection

Ceribell has secured breakthrough device designation from the FDA for its LVO Stroke monitoring tool, aimed at detecting large vessel occlusion strokes in hospitalized patients. The system leverages the company’s existing point-of-care EEG platform, including a 10-electrode headband and recorder, combined with AI algorithms to assess EEG signals for early stroke indicators.

Research shows approximately 800,000 strokes occur annually in the US, with up to 75,000 happening in hospitals, where delayed interventions can worsen outcomes. Early detection is crucial, and Ceribell’s solution targets this critical window.

Following the announcement, Ceribell shares rose about 4% to $22.48 on Nasdaq, with a market cap of roughly $823 million.

The breakthrough designation supports Ceribell’s strategy to expand EEG applications beyond seizure and delirium monitoring, building on prior FDA clearances, including pediatric electrographic seizure monitoring. The patient monitoring market is projected to reach $25.5 billion by 2034, growing at a CAGR of 1.8%.

07-01-2026